Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells

Neoplasia

Volumn 13, Issue 3, 2011, Pages 230-243

  Haim, Karin ^a   Weitzenfeld, Polina ^a   Meshel, Tsipi ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 79952401722     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101340     Document Type: Article

References (59)

1. Keeley EC, Mehrad B, and Strieter RM (2008). Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 28, 1928-1936.
2. Waugh DJ and Wilson C (2008). The interleukin-8 pathway in cancer. Clin Cancer Res 14, 6735-6741.
3. Chen JQ and Russo J (2009). ERa-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 1796, 162-175.
4. Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, and Murphy WJ (2002). Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin Cancer Res 8, 2655-2665.
5. Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF, and Wang SM (2007). Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 121, 1949-1957.
6. Yao C, Lin Y, Ye CS, Bi J, Zhu YF, andWang SM (2007). Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. ChinMed J (Engl) 120, 1766-1772.
7. Snoussi K, Mahfoudh W, Bouaouina N, Fekih M, Khairi H, Helal AN, and Chouchane L (2010). Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 10, 283.
8. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S, and Lazennec G (2007). Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9, R15.
9. Ben-Baruch A (2006). Pro-malignancy and Putative Anti-malignancy Chemokines in the Regulation of Breast Cancer Progression. Nova Science Publishers,NewYork, NY.
10. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, and Massagué J (2009). Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326.
11. Arpino G, Wiechmann L, Osborne CK, and Schiff R (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29, 217-233.
12. Fox EM, Andrade J, and Shupnik MA (2009). Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 74, 622-627.
13. Pietras RJ (2003). Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 9, 361-373.
14. Osborne CK and Schiff R (2003). Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12, 362-367.
15. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, and Yue W (2009). Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74, 586-594.
16. Lichtner RB (2003). Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 57, 447-451.
17. Amit I, Wides R, and Yarden Y (2007). Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 3, 151.
18. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, and Normanno N (2008). The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214, 559-567.
19. Lurje G and Lenz HJ (2009). EGFR signaling and drug discovery. Oncology 77, 400-410.
20. Johnston SR (2009). Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(suppl 1), S28-S36.
21. Fischer OM, Streit S, Hart S, and Ullrich A (2003). BeyondHerceptin and Gleevec. Curr Opin Chem Biol 7, 490-495.
22. Huang Z, Brdlik C, Jin P, and Shepard HM (2009). A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 9, 97-110.
23. Janni W and Hepp P (2010). Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 36, 249-261.
24. Cleator SJ, Ahamed E, Coombes RC, and Palmieri C (2009). A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 9(suppl 1), S6-S17.
25. Howell A (2008). The endocrine prevention of breast cancer. Best Pract Res Clin Endocrinol Metab 22, 615-623.
26. Prenzel N, Zwick E, Leserer M, and Ullrich A (2000). Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res 2, 184-190.
27. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, and Czerwenka K (2003). Co-expression of ErbB-family members in human breast cancer: Her-2/ neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80, 353-361.
28. Citri A and Yarden Y (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505-516.
29. Harari D and Yarden Y (2000). Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102-6114.
30. Johnston SR, Martin LA, Leary A, Head J, and Dowsett M (2007). Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 106, 180-186.
31. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, and Ben-Baruch A (2002). The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62, 1093-1102.
32. Hellmuth M, Wetzler C, Nold M, Chang JH, Frank S, Pfeilschifter J, and Mühl H (2002). Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate. Carcinogenesis 23, 1273-1279.
33. Levin ER (2009). Membrane oestrogen receptor a signalling to cell functions. J Physiol 587, 5019-5023.
34. Maggiolini M and Picard D (2010). The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 204, 105-114.
35. Mizukami Y (2010). In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J 57, 101-107.
36. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, and Nicholson RI (2005). Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(suppl 1), S99-S111.
37. Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu Y-L, Troup S, et al. (2006). Potential role of estrogen receptora(ERa) phosphorylated at serine118 in human breast cancer in vivo. J Steroid BiochemMol Biol 102, 139-146.
38. Kabos P and Borges VF (2010). Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother 11, 807-816.
39. Johnston SJ and Cheung KL (2010). Fulvestrant-a novel endocrine therapy for breast cancer. Curr Med Chem 17, 902-914.
40. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, et al. (2002). Phosphorylation of human estrogen receptor a at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21, 4921-4931.
41. Joel PB, Traish AM, and Lannigan DA (1998). Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273, 13317-13323.
42. Bunone G, Briand PA, Miksicek RJ, and Picard D (1996). Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 15, 2174-2183.
43. Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R, and Lazennec G (2007). CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14, 1039-1052.
44. Fong YC, Maa MC, Tsai FJ, Chen WC, Lin JG, Jeng LB, Yang RS, Fu WM, and Tang CH (2008). Osteoblast-derivedTGF-β1 stimulates IL-8 release through AP-1 and NF-κB in human cancer cells. J Bone Miner Res 23, 961-970.
45. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F, and Lazennec G (2004). Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23, 6105-6114.
46. Chavey C, Mühlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, Jobin C, and Lazennec G (2008). Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-κB pathway in breast cancer. Mol Pharmacol 74, 1359-1366.
47. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, and Ben-Neriah Y (1995). Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 92, 10599-10603.
48. Hartl M, Bader AG, and Bister K (2003). Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets 3, 41-55.
49. Shaulian E and Karin M (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-E136.
50. Vazquez-Martin A, Colomer R, and Menendez JA (2008). Her-2/neu-induced "cytokine signature" in breast cancer. Adv Exp Med Biol 617, 311-319.
51. Bendrik C and Dabrosin C (2009). Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 182, 371-378.
52. Platet N, Cathiard AM, Gleizes M, and Garcia M (2004). Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51, 55-67.
53. Keen JC and Davidson NE (2003). The biology of breast carcinoma. Cancer 97, 825-833.
54. Fuqua SA (2001). The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia 6, 407-417.
55. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, and Lazennec G (2003). IL-8 expression and its possible relationship with estrogenreceptor- negative status of breast cancer cells. Oncogene 22, 256-265.
56. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, and Huang RP (2004). Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109, 507-515.
57. Dowsett M (2001). Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8, 191-195.
58. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, et al. (2006). A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103, 7795-7800.
59. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, and Dowsett M (2003). Enhanced estrogen receptor (ER) a, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J Biol Chem 278, 30458-30468.